With an FDA review underway, Johnson & Johnson is aiming to “fundamentally change” how bladder cancer is treated. | With an ...

Akeso has shared for the first time overall survival data from a high-profile Keytruda head-to-head trial for its PD-1xVEGF ...

Summer is creeping closer, and for Gilead Sciences that only means one thing: the much-anticipated launch of long-acting HIV ...

Following a positive readout for its closely watched PD-1xVEGF bispecific ivonescimab, Akeso has won the FDA’s go-ahead for ...

Merck KGaA’s protracted pursuit of SpringWorks Therapeutics may be nearing its endgame. | Merck KGaA’s protracted pursuit of ...

With the threat of Trump administration's tariffs swirling and biopharma companies bracing for impact, many are announcing ...

After unveiling a new drug substance facility in North Carolina in December, Amgen is doubling down on expanding its U.S. | Amgen is plugging $900 million into an expansion of its biomanufacturing ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

While much of the conversation around the Trump administration’s potential pharmaceutical import tariffs has leaned heavily ...

Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of ...

Halozyme is not holding back against Merck & Co. in the companies' injectable Keytruda patent dispute, having now escalated a ...

On the heels of a clinical setback for Bristol Myers Squibb’s schizophrenia newcomer Cobenfy, the New Jersey pharma is ...